Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Part 1: To evaluate the efficacy of AIN457 at 6 weeks based on the proportion of patients achieving an ASAS20 response Part 2: To evaluate the efficacy of lower doses of AIN457 at 6 weeks based on the change in BASDAI score
Critère d'inclusion
- Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA)